-

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST).

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Contacts

Incyte Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Incyte

NASDAQ:INCY

Release Versions

Contacts

Incyte Contacts

Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma...

Incyte Announces Change to its Board of Directors

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Change to its Board of Directors...

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

WILMINGTON, Del.--(BUSINESS WIRE)--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET...
Back to Newsroom